RxDoctor Payments Data

Crystal Kaplan

Acute Care · Henderson, NCNPI 1124584206

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 100 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 26 manufacturers, the largest accounting for just 10.5% — the pattern of someone who eats at a lot of different presentations.

$1,950in general payments, 2019–2025

Across 100 payments — averaging $19.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$205
  • Bristol Myers Squibb$196
  • Daiichi Sankyo Inc.$170
  • Merck$139
  • E.r. Squibb & Sons, L.L.C.$127
  • Array Biopharma Inc$120
  • plus $993 from 20 others

What the payments were for

  • Food & beverage$1,950100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,950 in reported general payments places this provider in the 85th percentile of 312 acute care providers in North Carolina.

See all acute care providers in North Carolina

Medicare billing

Part B allowed, 2024
$13,581
Medicare patients
121
Services billed
166

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban18$15,720
Exemestane15$3,711
Letrozole47$1,103
Anastrozole13$364
Ibandronate Sodium14$354
Hydroxyurea15$275
Prochlorperazine Maleate11$200
Oxycodone Hcl11$160
Prednisone15$78

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$205$15,72018 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 312 acute care providers in North Carolina.

Other acute care in Henderson

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →